Abstract ▼ AI-Helper

Cheongnoemyeongsin-hwan (CNMSH) is a novel developed medicinal formula in order to improve memory and treat dementia. Recently it has been reported that CNMSH may be a useful treatment for neurodegenerative disease by inhibiting inflammatory responses in activated microglia. However, the physiologic...

Cheongnoemyeongsin-hwan (CNMSH) is a novel developed medicinal formula in order to improve memory and treat dementia. Recently it has been reported that CNMSH may be a useful treatment for neurodegenerative disease by inhibiting inflammatory responses in activated microglia. However, the physiological effects of CNMSH still remain largely unresolved; the aim of this study was to investigate the safety of CNMSH by single dose toxicity study in mice. CNMSH was orally administered at a dose of 5,000 mg/kg in ICR mice. All animals were sacrificed after 14 days of treatment. After single administration, mortality, clinical signs, body weight changes and gross pathological findings were observed for 14 days. We also measured the parameters of the organ weight, clinical chemistry and hematology. No toxicological change related to the test substance nor mortality was observed after administration of a single oral dose of CNMSH in mice. There were no adverse effects on clinical signs, body weight, organ weight and gross pathological findings at all treatment groups. The clinical chemistry and hematological parameters were attesting within the normal ranges. Therefore, the approximate lethal dose for oral administration of CNMSH in mice was considered to be over 5,000 mg/kg. The results on the single-dose toxicity of CNMSH indicate that it is not possible to reach oral dose levels related to death or dose levels with any harmful side-effects.